When diabetes causes frayed nerves

Through its targeted three-fold effect, Alpan® effectively alleviates abnormal sensations caused by diabetes such as burning, numbness, and pain in the feet and hands.

The function of already damaged nerves is improved and they are protected from further diabetes attacks. The impaired blood sugar break down as central cause is counteracted.

With its active ingredient thioctic acid, a co-enzyme important for the sugar metabolism and formed in the body, Alpan® has a three-fold effect and is well tolerated at the same time. Alpan® acts naturally without straining the body. This is particularly important for long-term intake.

More information available at www.alpan.de

  • Application areas
    Dysaesthesia in diabetic polyneuropathy.
  • Drug and composition
    One capsule contains alpha-lipoic acid 300 mg. Excipient: Sorbitol.

    Thioctic acid

    For other ingredients refer to the Direction for use.
  • Dosage and method of administration
    In dysaesthesia in diabetic polyneuropathy the recommended daily dosage for adults is two Alpan® 300 Weichkapseln per day (equals 600 mg alpha-lipoic acid), that should be taken in a single dose approximately 30 minutes before the first meal of the day. In sever cases of dysaesthesia, an initial treatment using alpha-lipoic acid infusions may be given.

    Alpan® 300 Weichkapseln should be taken whole with sufficient fluid on an empty stomach. The simultaneous consumption of food may hinder resorption. It is therefore particularly important in patients with a prolonged stomach emptying time that the capsules are taken half an hour before breakfast.

    As diabetic polyneuropathy is a chronic disease, long-term therapy may be required. A fundamental requirement of diabetic polyneuropathy therapy is an optimum adjustment of the blood sugar level.
  • Package Sizes
    • 30 60 120 Soft Capsules - PZN 09674332 09674349 09674355
  • Required text
    Alpan® 300 mg Weichkapseln. Active substance: Alpha-lipoic acid. Therapeutic indications: Dysaesthesia in diabetic polyneuropathy. If you have any questions about risks and side effects, please read the patient information leaflet and ask your doctor or pharmacist. WÖRWAG Pharma GmbH & Co. KG, 71034 Böblingen
  • Downloads

Further products